Quarterly results round-up: US Sapien sales drive up Edwards' Q2; QGEN, TMO, VAR
This article was originally published in Clinica
Edwards Lifesciences saw its bottom and top lines grow during its second fiscal quarter, driven by increasing US sales of its Sapien transcatheter heart valve, which offset softness in Europe. Morgan Stanley analyst David Lewis described the European market as "a challenge", but said the problems there "could not overshadow Sapien['s] performance in the US". US Sapien sales of $61m in Q2 outpaced the analyst's forecast of $53m.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.